Ex-Baxalta CEO Ludwig Hantson gets the top job at a troubled Alexion
So Ludwig Hantson will get his chance to run a biotech company after all.
A little less than nine months after Shire closed on its deal to buy Baxalta, a new spinout out of Baxter, for $32 billion, the former CEO at Baxalta now has the top job at Alexion.
Hantson had run Baxter BioScience before they gave him the reins at Baxalta, giving him a run at operating a $6 billion group responsible for launching 13 products. Shire, though, leaped on the buyout shortly after it was spun out. Now he’ll be stepping into a vacancy created by a marketing scandal that took down both the CEO and the CFO, who were entangled in a scheme to push early sales of Soliris in order to meet Wall Street’s revenue expectations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.